CytRx Corporation to Participate on the "Risk-Reduced Models for the Biotech Industry" Panel at BIO 2008 International Convention

Business Wire,  June 16, 2008  

• E-mail
• Print
• Link

LOS ANGELES -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that David Haen, Vice President of Business Development, will participate in the "Risk-Reduced Models for the Biotech Industry" panel at the BIO 2008 International Convention in San Diego on June 18.

A panel of biotech experts, executives and investors will gather at BIO to discuss successful business models that mitigate risk. For the second year running, the panel educates the audience on emerging trends for expediting drug development and adding value to investors.

Details of the panel follow:  <

                              <
Risk-Reduced Models for the Biotech Industry
                              <
Wednesday, June 18, 2008
                              <
4:00 PM - 5:00 PM PDT (7:00 PM - 8:00 PM EDT)
                              <
San Diego Convention Center, Room 31ABC

For more information about BIO 2008, visit www.bio2008.org.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company has three clinical-stage development programs based on its small-molecule "molecular chaperone" co-induction technology. CytRx owns and operates a research and development facility in San Diego. The Company has also recently signed a definitive agreement to acquire Innovive Pharmaceuticals, Inc., a biopharmaceutical company with a pipeline of oncology therapeutic drug candidates. CytRx also maintains a 49% equity interest in RXi Pharmaceuticals (Nasdaq: RXII). For more information on the Company, visit www.cytrx.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning